Dose in First Treatment Period, Subgroup (n) | Improved SL and TST at Week 4, n (%) | Not Eligible, n | Eligiblea, n |
---|---|---|---|
Elderly | |||
1 mg, with psychiatric disorders (n = 34) | 29 (85.3) | 32 | 2 |
2 mg, with psychiatric disorders (n = 42) | 39 (92.9) | 41 | 1 |
1 mg, without psychiatric disorders (n = 40) | 34 (85.0) | 38 | 2 |
2 mg, without psychiatric disorders (n = 36) | 32 (88.9) | 35 | 1 |
Total elderly (n = 152) | 134 (88.2) | 146 | 6 |
Nonelderly | |||
2 mg, with psychiatric disorders (n = 41) | 36 (87.8) | 39 | 2 |
3 mg, with psychiatric disorders (n = 35) | 28 (80.0) | 32 | 3 |
2 mg, without psychiatric disorders (n = 41) | 31 (75.6) | 36 | 5 |
3 mg, without psychiatric disorders (n = 38) | 33 (86.8) | 37 | 1 |
Total nonelderly (n = 155) | 128 (82.6) | 144 | 11 |